Ubix Therapeutics, Inc. develops novel anti-cancer drugs based on Degraducer,
target protein degradation platform technology.

Research

Degraducer® is a technology that utilizes the UPS system, an intracellular purification system. Degraducer® is a bifunctional molecule where “ligand”, which binds to target protein, and “binder”, which binds to E3 ubiquitin ligase, are connected by a linker. In other words, Degraducer® is a powerful inhibitor technology that enables target protein degradation and consequent therapeutic effects by placing a disease-related target protein nearby E3 ligase, which can then initiate the protein degradation system.

Partnership

Ubix Therapeutics, Inc. is focused on developing cancer immunotherapy based on experience and expertise in Cell Signaling Pathway and Epigenetics research. We are aware that in order to do so successfully, close cooperation with our partners are the most important, and thus we are consistently looking forward to form partnerships in various R&D and business fields.
Based on mutualistic partnerships and outstanding technology capable of international competition, Ubix Therapeutics, Inc. will jump beyond the border to become a world-class bio company.

Notice

Contact

Headquarter
ADDRESS
(05836) #1512, 7, Beobwon-ro 11-gil, Songpa-gu, Seoul, Republic of Korea
TEL
02-6335-2475
FAX
02-6334-2475
E-MAIL
info@ubixtrx.com
Research Center(Biology)
ADDRESS
(05836) #1508, 7, Beobwon-ro 11-gil, Songpa-gu, Seoul, Republic of Korea
TEL
02-6335-2476
FAX
02-6334-2476
E-MAIL
bio@ubixtrx.com
Research Center(Chemistry)
ADDRESS
(21984) #1603, 32, Songdogwahak-ro, Yeonsu-gu, Incheon, Republic of Korea
TEL
032-225-2477
FAX
032-215-2477
E-MAIL
chem@ubixtrx.com